# EMPEROR-Preserved

Study · id `cardio:emperor-preserved` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Empagliflozin outcome trial in heart failure with preserved ejection fraction

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A large trial in adults with heart failure and an ejection fraction above 40%. About half were given empagliflozin 10 mg once a day and half a placebo, on top of usual treatment. Over a median of about 26 months, fewer people on empagliflozin died from cardiovascular causes or were admitted to hospital for heart failure. The authors say this effect was mainly due to fewer hospital admissions for heart failure. Genital and urinary tract infections and low blood pressure were reported more often with empagliflozin.

## Technical summary

Boehringer Ingelheim-sponsored (Eli Lilly and Company is a registry collaborator), randomized, double-blind, placebo-controlled phase 3 trial (NCT03057951) of 5988 patients with NYHA class II to IV heart failure and an ejection fraction of more than 40%. Primary outcome: cardiovascular death or hospitalization for heart failure, hazard ratio 0.79 (95% CI 0.69 to 0.90) over a median of 26.2 months, from the PubMed abstract. The abstract says the effect was mainly related to a lower risk of hospitalization for heart failure. The registry title and official title say preserved ejection fraction; the abstract entry criterion is an ejection fraction above 40%, so the trial includes people whom a US government patient page would call borderline (41% to 49%). The full text was not read. Funding is stated in the abstract as Boehringer Ingelheim and Eli Lilly.

## Key facts

- Design: Randomized, parallel-group, double-blind, placebo-controlled phase 3 trial of empagliflozin 10 mg once daily added to usual therapy in people with an ejection fraction above 40%. The abstract calls it double-blind and the registry records masking as double.
- Phase: Phase 3
- Enrolled: 5988 patients (randomized count; Empagliflozin in Heart Failure with a Preserved Ejection Fraction, snapshot `cardio:pubmed-34449189-2026-10-14`, retrieved 2026-10-14)
- Started: 2017-03-02 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2021-04-26 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)
- Completion: 2021-04-26 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2022-06-06 (actual) (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; China; Colombia; Czechia; Germany; Hungary; India; Italy; Japan; Mexico; Netherlands; Poland; Romania; Singapore; South Africa; South Korea; Spain; United Kingdom (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct03057951-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests this medicine: Empagliflozin (`cardio:empagliflozin`)
- Studies people with this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Lead sponsor on the registry record: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Collaborator on the registry record: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 02a8d7eb341ec63b2eb15efcff52185691dd123f08479539141ddcee44f1f12e
Last substantive edit: 2026-10-15
Evidence last checked: 2026-10-14